遗传决定的NLRP3炎症小体激活与全身炎症及心血管死亡相关
rs10754555变异携带者C反应蛋白和血清淀粉样A水平更高、NLRP3炎症小体激活更强,冠心病患病率及心血管死亡风险显著增高。提示遗传驱动的全身炎症在心血管病中起重要作用,NLRP3炎症小体为治疗靶点。
要点
- rs10754555变异携带者全身炎症标志物升高且NLRP3炎症小体激活增强。
- 该变异携带者冠心病患病率显著更高,且与年龄存在显著交互作用。
- 该变异携带者随访期间心血管死亡风险显著增高。
核心结论
- NLRP3内含子变异rs10754555与全身炎症增加、炎症小体激活、冠心病患病及死亡相关。
- 研究为遗传驱动的全身炎症在心血管病中的作用提供证据,并突出NLRP3炎症小体作为治疗靶点。
研究设计与样本
- 在单核细胞富集的外周血单个核细胞中评估单核苷酸多态性对NLRP3炎症小体激活的功能相关性。
主要发现
- rs10754555次要等位基因频率为39.9%,影响NLRP3基因表达。
- rs10754555携带者C反应蛋白和血清淀粉样A血浆水平显著更高。
- G等位基因携带者分离的人外周血单个核细胞中NLRP3炎症小体激活更高。
- rs10754555携带者冠心病患病率显著高于非携带者,且rs10754555与年龄存在显著交互作用。
- rs10754555携带者随访期间心血管死亡风险显著更高,炎症小体诱导物(如尿酸盐、甘油三酯、载脂蛋白C3)可调节该变异与死亡率的关联。
临床怎么用
- rs10754555基因分型可能有助于识别全身炎症驱动的心血管病高风险个体。
- NLRP3炎症小体通路(如白细胞介素-1β)是潜在治疗靶点,但需进一步临床验证。
局限性
- 研究为探索性基因中心分析,未进行多重检验校正。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Inflammation plays an important role in cardiovascular disease (CVD) development. The NOD-like receptor protein-3 (NLRP3) inflammasome contributes to the development of atherosclerosis in animal models. Components of the NLRP3 inflammasome pathway such as interleukin-1β can therapeutically be targeted. Associations of genetically determined inflammasome-mediated systemic inflammation with CVD and mortality in humans are unknown. METHODS AND RESULTS: We explored the association of genetic NLRP3 variants with prevalent CVD and cardiovascular mortality in 538 167 subjects on the individual participant level in an explorative gene-centric approach without performing multiple testing. Functional relevance of single-nucleotide polymorphisms on NLRP3 inflammasome activation has been evaluated in monocyte-enriched peripheral blood mononuclear cells (PBMCs). Genetic analyses identified the highly prevalent (minor allele frequency 39.9%) intronic NLRP3 variant rs10754555 to affect NLRP3 gene expression. rs10754555 carriers showed significantly higher C-reactive protein and serum amyloid A plasma levels. Carriers of the G allele showed higher NLRP3 inflammasome activation in isolated human PBMCs. In carriers of the rs10754555 variant, the prevalence of coronary artery disease was significantly higher as compared to non-carriers with a significant interaction between rs10754555 and age. Importantly, rs10754555 carriers had significantly higher risk for cardiovascular mortality during follow-up. Inflammasome inducers (e.g. urate, triglycerides, apolipoprotein C3) modulated the association between rs10754555 and mortality. CONCLUSION: The NLRP3 intronic variant rs10754555 is associated with increased systemic inflammation, inflammasome activation, prevalent coronary artery disease, and mortality. This study provides evidence for a substantial role of genetically driven systemic inflammation in CVD and highlights the NLRP3 inflammasome as a therapeutic target.
引用
- Schunk SJ, Kleber ME, März W, et al. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. Eur Heart J. 2021. PMID: 33748830. doi:10.1093/eurheartj/ehab107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。